Physician profile
Michael Nuce
NPI 1750090882
$2,533.93
in general payments reported to CMS, 2019-2025
30 companies · $2,213 in 2025
The $2,213 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $321 · 2025: $2,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $297.27 | 2024-2025 | Nayzilam, Fintepla, Rystiggo |
| Jazz Pharmaceuticals INC. | $262.27 | 2025 | |
| Lundbeck LLC | $254.41 | 2024-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $186.24 | 2024-2025 | Ultomiris |
| Eisai INC. | $173.93 | 2024-2025 | |
| Pfizer INC. | $151.90 | 2025 | |
| Tg Therapeutics, INC. | $124.04 | 2025 | |
| Argenx US, INC. | $120.78 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $117.33 | 2025 | Daybue, Nuplazid |
| Trisalus Life Sciences, INC. | $114.60 | 2024-2025 | Trinav Infusion System |
| Neurocrine Biosciences, INC. | $80.48 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $76.83 | 2025 | |
| Janssen Biotech, INC. | $62.06 | 2025 | |
| Springworks Therapeutics, INC. | $60.55 | 2025 | Gomekli |
| Biogen, INC. | $53.36 | 2024-2025 | Vumerity, Avonex, Tysabri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $42.22 | 2025 | Austedo Xr |
| Genzyme Corporation | $41.41 | 2025 | |
| Novartis Pharmaceuticals Corporation | $38.69 | 2024-2025 | |
| Sk Life Science, INC. | $32.55 | 2025 | |
| Lilly USA, LLC | $31.22 | 2025 | Amyvid, Kisunla |
| Abbvie INC. | $30.53 | 2025 | |
| Scilex Pharmaceuticals INC. | $24.65 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.93 | 2024 | Spravato |
| Ipsen Biopharmaceuticals, INC | $21.92 | 2025 | Dysport |
| Ani Pharmaceuticals, INC. | $21.13 | 2025 | Purified Cortrophin Gel |
| Averitas Pharma INC. | $20.98 | 2025 | Qutenza |
| Life Molecular Imaging LTD | $20.59 | 2025 | Neuraceq |
| Astrazeneca Pharmaceuticals LP | $18.30 | 2025 | Wainua |
| Takeda Pharmaceuticals U.S.A., INC. | $16.41 | 2024 | Hyqvia |
| Merz Pharmaceuticals, LLC | $14.35 | 2025 | Inbrija, Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nuce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.